Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies, focused on areas with identified technological advantage, superior clinical utility, and substantial market opportunity. The company has also pursued neurological therapies, including a concussion treatment program, though in December 2023 stockholders approved the sale of its neurological drug therapies and technologies to Oragenics, Inc. for $1 million in cash and 8 million shares of convertible preferred stock.
Cyborg Score Rationale
Odyssey operates as a micro-cap OTC company with minimal revenue generation, divested its lead clinical-stage asset (concussion drug), and relies primarily on product development-stage initiatives. Limited financial resources, volatile stock performance, and lack of commercialized products present material execution risk.
Top Insights
Company divested its most advanced asset (concussion treatment program) to Oragenics in December 2023, suggesting capital constraints or strategic pivot
Two primary product candidates (CardioMap and Save-A-Life) remain in development stage with no clear commercialization timeline
OTC trading status and micro-cap market valuation (~$1.7M as of June 2026) indicate limited liquidity and institutional investor access
Historical acquisition attempts (Speranza Therapeutics in June 2023) suggest M&A-driven growth strategy, though execution challenges persist